Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | TNG462 |
Synonyms | |
Therapy Description |
TNG462 is a PRMT5 inhibitor with selectivity for MTAP-deleted cells, which may decrease tumor growth (European J Cancer 174, 2022 (suppl 1, S84)). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TNG462 | TNG 462|TNG-462 | PRMT5 Inhibitor 16 | TNG462 is a PRMT5 inhibitor with selectivity for MTAP-deleted cells, which may decrease tumor growth (European J Cancer 174, 2022 (suppl 1, S84)). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05732831 | Phase Ib/II | TNG462 | Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | Recruiting | USA | FRA | ESP | 0 |